Results 151 to 160 of about 182,825 (308)

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

open access: yesBMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu   +5 more
wiley   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

open access: yesBMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo   +9 more
wiley   +1 more source

Single‐Cell Profiling Reveals Distinct Immune Hallmarks in Untreated Primary Colorectal and Liver Metastasis Cancers

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Features the major cell type compositions among colon and liver metastasis. (A) The study design for single‐cell data analysis. (B) The annotated major cell types. Each type was labeled with a special color. (C) Dot plot of canonical marker genes for major cell types. (D) Bar plot of the percentage for each cell type in individuals. (E) Bar plot of the
Zhixun Zhao   +10 more
wiley   +1 more source

Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis

open access: yesWorld Journal of Surgical Oncology
Objective Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib and niraparib have shown promise in extending progression-free survival (PFS) in patients with platinum-sensitive recurrent (PSR) epithelial ovarian cancer.
Yumei Zhou, Junfen Xu
doaj   +1 more source

Polo like kinase 2 tumour suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer [PDF]

open access: yes, 2012
The polo-like kinase PLK2 has recently been identified as a potential theranostic marker in the management of chemotherapy sensitive cancers. The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian ...
Mcneish, I.   +13 more
core  

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

open access: yesChemistry – A European Journal, EarlyView.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias   +9 more
wiley   +1 more source

Living Microbial Drugs

open access: yesChemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik   +3 more
wiley   +1 more source

Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9

open access: yesCytoskeleton, EarlyView.
ABSTRACT The unbranched actin filaments in mammalian cells are usually composed of co‐polymers of a specific tropomyosin isoform with actin. Genetic manipulation has revealed that the tropomyosins largely define the functional properties of actin filaments in an isoform‐specific, non‐redundant manner.
Jeff Hook   +2 more
wiley   +1 more source

From Metabolic Crisis to Molecular Classification: Multidisciplinary Management of Synchronous Endometrioid Ovarian and Endometrial Carcinomas With Massive Tumor Burden

open access: yesCancer Nexus, EarlyView.
Managing massive tumor burden in synchronous endometrioid carcinomas. The graphical abstract summarizes the clinical pathway from presentation with massive ascites, pleural effusion, and critical metabolic abnormalities to multidisciplinary stabilization, surgical management, integrated morphologic–molecular classification, and shared decision‐making ...
Anna Homeniuk   +2 more
wiley   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy